<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109137">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01747564</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-093</org_study_id>
    <nct_id>NCT01747564</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects</brief_title>
  <official_title>A Study to Evaluate Pharmacokinetics of Mirabegron After Single and Multiple Oral Administration to Healthy Non-elderly Male and Female Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and absorption, distribution and elimination
      of mirabegron after oral administration to Chinese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label study.  The subjects will receive single administration of
      mirabegron in a fasted condition.  After the non-dosing period, subjects will receive
      mirabegron for 8 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile for ASP015K (in plasma): Cmax, AUClast, AUCinf and AUC0-24h</measure>
    <time_frame>Day 1-5 and Day 10, 11, 14-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum concentration (Cmax), Area under the curve (AUC) from time 0 extrapolated to infinity (AUCinf), AUC from time of dosing to last quantifiable concentration (AUClast ), and AUC from time 0 to 24hr (AUC0-24h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, lab-test and 12-lead ECGs</measure>
    <time_frame>Through day 25</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Plasma Concentration of Mirabegron</condition>
  <arm_group>
    <arm_group_label>mirabegron group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM178 (mirabegron)</intervention_name>
    <description>oral</description>
    <arm_group_label>mirabegron group</arm_group_label>
    <other_name>mirabegron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: (male) over 50.0kg and less than 80.0kg (female) over 40.0kg and less
             than 70.0kg

          -  Body Mass Index: over 17.6 and less than 26.4 kg/m

          -  Chinese subjects

          -  Healthy judged by investigator or sub-investigator

        Exclusion Criteria:

          -  Received any investigational drugs within 120 days before the screening assessment

          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days,
             or blood components within 14 days before the screening assessment

          -  Received medication within 7 days before hospital admission

          -  A deviation from the assessment criteria of physical examinations or laboratory tests
             at screening or upon admission

          -  History of drug allergies

          -  With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases

          -  Received mirabegron beforehand

          -  Glaucoma patient
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 10, 2012</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Phase 1</keyword>
  <keyword>YM178</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
